Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, announced that ...
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comme...
Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease prog...
— $9M Second Phase of CDMO Investment Builds on 2025 $6M Expansion, Funding Facility Upgrades and Increased Capacity for Suppository, Semi-Solid,...
TRI-611 is an oral investigational small molecule therapy designed as a potent, brain-penetrant molecular glue degrader, engaging the body’s in...
Reimagining early-stage drug discovery leveraging NVIDIA BioNeMo Framework -- Persistent Systems (BSE: 533179) (NSE: PERS...
Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease The US Food and Drug Administration (FDA...
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in...
Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a trans...
Taiwan Bio will leverage the Quantum Flex™ Cell Expansion System 3-in-1 workflow beyond CAR-T to support&nb...
-Johnson & Johnson announced the arrival in Peru of a new pulsed field ablation (PFA) technology for the treatment of drug-refractory paroxysmal atri...
YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced that the U.S. Food and Drug ...
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery...
23andMe, a leading consumer genetics and research organization and nonprofit affiliate of the 23andMe Research Institute, today announced the launch of a...
© 2026 Biopharma Boardroom. All Rights Reserved.
